- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04233359
A Randomised Study Evaluating Diagnostics of Pleural Effusion Among Patients Suspect of Cancer.
Local Anesthetic Thoracoscopy Versus Ultrasound Guided Pleural Biopsies and Repeat Thoracocentesis in Pleural Effusion After Inconclusive Initial Thoracentesis: a Randomized Study
Pleural fluid can be caused by cancer. Patients with repeated presentation of pleural fluid where initial diagnostic tests have been inconclusive are the focus of this trial. In this clinical trial patients are randomized into two groups and the efficacy of local anesthetic thoracoscopy (LAT) is compared to an ultrasound guided biopsy of the outer lining of the lung. The aim is not only the diagnostic yield in diagnosing cancer, but also the procedures ability to diagnose specific cancer mutations and immune system markings.
Methods and objectives:
Patients with reoccuring one-sided pleural fluid, with a marked clinical risk of cancer based on findings in medical work-up, radiological scans, biochemistry and medical history and who are undiagnosed upon initial pleural fluid analysis are the target patients of the trial. Patients are randomized into two groups to have undertaken either pleural biopsy at the optimal site for a repeat thoracentesis or LAT. Thus diagnostic yield for both fluid analysis and biopsy analysis will be compared to tissue samples taken with LAT.
We hypothesize that LAT is superior both to pleural biopsy and repeat thoracentesis in providing diagnostic clarification and providing sufficient basis for treatment without further procedures resulting in less time consumption, cost and discomfort for the patient.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Næstved, Denmark, 4700
- Næstved Hospital
-
Roskilde, Denmark, 4000
- University Hospital Zealand, Roskilde
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18 years or older patients with single previous thoracentesis of a unilateral pleural exudate according to Lights criteria without malignant cells.
- Lights Criteria:
Pleural fluid protein/serum protein ratio greater than 0.5 pleural fluid LDH/serum LDH ratio greater than 0.6 Pleural fluid LDH greater than two-thirds the upper limits of the Laboratorys normal Serum LDH
- Contrast enhanced CT of the Chest and abdomen performed
- Clinical suspicion of cancer such as, but not limited to, weight loss, malaise, anemia
- Pet-CT results or former cancer diagnosis Informed consent
Exclusion Criteria:
- bilateral pleural effusions
- known cause of pleural effusion
- likely non-malignant course of a unilateral pleura effusion such as (but not restricted to) pneumonia, trauma, pleuritis, heart failure
- any contraindication to the study procedures
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: US-guided pleural biopsy and thoracentesis
Pleural biopsy: Using ultrasound the optimal point of entry for thoracentesis is located, and local anesthesia is obtained. The area is wiped with disinfectant and a skin incision is made with a pointed scalpel. Six US-guided biopsies of 1x2 millimetres are taken from the parietal pleura using closed needle biopsies (Quick-core Biopsy Needle 18G, COOK Medical, Bloomington, Indiana, USA or Bard Max Core Biopsy Needle 18G, Tempe, Arizona, USA). Afterward, a thoracentesis is performed in the same incision as used by the pleural biopsy. A pigtail catheter is inserted and fastened and connected to a sealed bag and fluid is aspirated and sent to relevant analysis. |
In local anesthesia, a closed needle biopsy is performed Ultrasound guided of the parietal pleura at the place of deepest fluid recess in the intrathoracic space.
A pigtail catheter French 7-16 is placed afterwards for fluid drainage.
|
Experimental: LAT and thoracentesis
Local anesthetic thoracoscopy: Pre-procedure a pleural pigtail catheter is inserted and pleural fluid is removed.
The catheters one-way valve is opened and the patient takes several breaths thereby creating a pneumothorax prior to procedure start.
The patient is sedated with midazolam and morphine.
Midaxillary access through intercostal space 4-7 is achieved in local anesthesia and via a skin incision a trocar is placed for access to the thoracic space.
A semi-rigid thoracoscope (model LTF 160; Olympus, Tokyo, Japan) is inserted via the trocar and the pleural cavity is inspected after removal of residual effusion whereof at least 40ml is sent to cytology.
Pleural parietal biopsies are taken under direct visual guidance.
The recommended number of biopsies is 10-15.
If no abnormalities were seen, random biopsies are taken.
After relevant biopsies are taken the instruments are removed the pigtail catheter stays inserted to allow for removal of air and expansion of the lung.
|
Procedure to obtain histological biopsies of the parietal pleura on awake, fastening patients.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of treatment-guiding pleural workup to provide and plan treatment for the cause of the pleura exudate, local anesthetic thoracoscopy vs 2. thoracentesis
Time Frame: 26 weeks
|
Difference in incidence of treatment-guiding diagnostic workup in local anesthetic thoracoscopy versus 2nd thoracentesis
|
26 weeks
|
Incidence of treatment-guiding pleural workup to provide and plan treatment for the cause of the pleura exudate. Local anesthetic thoracoscopy vs US-guided pleural biopsy.
Time Frame: 26 weeks
|
Difference in incidence of treatment-guiding diagnostic workup in local anesthetic thoracoscopy versus US-guided pleural biopsy prior to 2nd thoracentesis
|
26 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of achieving pleural immunohistochemistry, mutations, oncodrivers, culture and biochemistry.
Time Frame: 26 weeks
|
26 weeks
|
|
Incidence of completed procedures
Time Frame: 1 week
|
1 week
|
|
Time from randomization to conclusive, treatment-guiding diagnoses
Time Frame: 26 weeks
|
26 weeks
|
|
Time from start of consultation with medical staff until end of consultation with medical staff on the day of the procedure
Time Frame: Day of procedure/intervention
|
Day of procedure/intervention
|
|
Time from procedure start to patient leaving the procedure room and leaving the recovery room
Time Frame: Day of procedure/intervention
|
Day of procedure/intervention
|
|
Adverse event; complication to procedure: mortality
Time Frame: 30 days.
|
Evaluated on day of procedure, 7 days and 30 days.
The 2 last are performed via telephone call to the patient and informations gathering in the electronic patient file system
|
30 days.
|
Adverse event; complication to procedure: pneumothorax
Time Frame: 30 days.
|
Evaluated on day of procedure, 7 days and 30 days.
The 2 last are performed via telephone call to the patient and informations gathering in the electronic patient file system
|
30 days.
|
Adverse event; complication to procedure: haemoptysis
Time Frame: 30 days.
|
Evaluated on day of procedure, 7 days and 30 days.
The 2 last are performed via telephone call to the patient and informations gathering in the electronic patient file system
|
30 days.
|
Adverse event; complication to procedure: infection
Time Frame: 30 days.
|
Evaluated on day of procedure, 7 days and 30 days.
The 2 last are performed via telephone call to the patient and informations gathering in the electronic patient file system
|
30 days.
|
Adverse event; complication to procedure: hospital admission
Time Frame: 30 days.
|
Evaluated on day of procedure, 7 days and 30 days.
The 2 last are performed via telephone call to the patient and informations gathering in the electronic patient file system
|
30 days.
|
Total volume of pleural fluid removed
Time Frame: Day of procedure
|
In mililiter (ml)
|
Day of procedure
|
Patient reported discomfort reported via ESAS
Time Frame: Day of procedure pre- and post-procedure and 1 week followup
|
ESAS - Edmonton Symptom Assesment System, Danish Version 2008
|
Day of procedure pre- and post-procedure and 1 week followup
|
Patient reported discomfort reported via EQ-5D-5L
Time Frame: Day of procedure pre- and post-proceudre and 1 week followup
|
Denmark (Danish) © 2009 EuroQol Group EQ-5D™
|
Day of procedure pre- and post-proceudre and 1 week followup
|
Willingness to repeat procedure
Time Frame: After procedure performed - within 30 minutes and 1 week after proceudre
|
5 Point Likert Scale, 1 not likely to repeat, 5 most likely to repeat
|
After procedure performed - within 30 minutes and 1 week after proceudre
|
Cough
Time Frame: Pre-procedure, 1 week post procedure.
|
Visual analogue scale 1-10. 1 Being no cough, 10 being extreme cough
|
Pre-procedure, 1 week post procedure.
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Uffe Bødtger, MD ph.d., Næstved
Publications and helpful links
General Publications
- Roberts ME, Neville E, Berrisford RG, Antunes G, Ali NJ; BTS Pleural Disease Guideline Group. Management of a malignant pleural effusion: British Thoracic Society Pleural Disease Guideline 2010. Thorax. 2010 Aug;65 Suppl 2:ii32-40. doi: 10.1136/thx.2010.136994. No abstract available.
- Hooper C, Lee YC, Maskell N; BTS Pleural Guideline Group. Investigation of a unilateral pleural effusion in adults: British Thoracic Society Pleural Disease Guideline 2010. Thorax. 2010 Aug;65 Suppl 2:ii4-17. doi: 10.1136/thx.2010.136978. No abstract available.
- Light RW, Macgregor MI, Luchsinger PC, Ball WC Jr. Pleural effusions: the diagnostic separation of transudates and exudates. Ann Intern Med. 1972 Oct;77(4):507-13. doi: 10.7326/0003-4819-77-4-507. No abstract available.
- Saks AM, Posner R. Tuberculosis in HIV positive patients in South Africa: a comparative radiological study with HIV negative patients. Clin Radiol. 1992 Dec;46(6):387-90. doi: 10.1016/s0009-9260(05)80684-1.
- Arnold DT, De Fonseka D, Perry S, Morley A, Harvey JE, Medford A, Brett M, Maskell NA. Investigating unilateral pleural effusions: the role of cytology. Eur Respir J. 2018 Nov 8;52(5):1801254. doi: 10.1183/13993003.01254-2018. Print 2018 Nov.
- Porcel JM, Esquerda A, Vives M, Bielsa S. Etiology of pleural effusions: analysis of more than 3,000 consecutive thoracenteses. Arch Bronconeumol. 2014 May;50(5):161-5. doi: 10.1016/j.arbres.2013.11.007. Epub 2013 Dec 20. English, Spanish.
- Marel M, Zrustova M, Stasny B, Light RW. The incidence of pleural effusion in a well-defined region. Epidemiologic study in central Bohemia. Chest. 1993 Nov;104(5):1486-9. doi: 10.1378/chest.104.5.1486.
- Bintcliffe OJ, Lee GY, Rahman NM, Maskell NA. The management of benign non-infective pleural effusions. Eur Respir Rev. 2016 Sep;25(141):303-16. doi: 10.1183/16000617.0026-2016.
- Porcel JM, Gasol A, Bielsa S, Civit C, Light RW, Salud A. Clinical features and survival of lung cancer patients with pleural effusions. Respirology. 2015 May;20(4):654-9. doi: 10.1111/resp.12496. Epub 2015 Feb 23.
- Orki A, Akin O, Tasci AE, Ciftci H, Urek S, Falay O, Kutlu CA. The role of positron emission tomography/computed tomography in the diagnosis of pleural diseases. Thorac Cardiovasc Surg. 2009 Jun;57(4):217-21. doi: 10.1055/s-2008-1039314. Epub 2009 May 20.
- Naito T, Satoh H, Ishikawa H, Yamashita YT, Kamma H, Takahashi H, Ohtsuka M, Hasegawa S. Pleural effusion as a significant prognostic factor in non-small cell lung cancer. Anticancer Res. 1997 Nov-Dec;17(6D):4743-6.
- Nance KV, Shermer RW, Askin FB. Diagnostic efficacy of pleural biopsy as compared with that of pleural fluid examination. Mod Pathol. 1991 May;4(3):320-4.
- Loddenkemper R, Boutin C. Thoracoscopy: present diagnostic and therapeutic indications. Eur Respir J. 1993 Nov;6(10):1544-55.
- Garcia LW, Ducatman BS, Wang HH. The value of multiple fluid specimens in the cytological diagnosis of malignancy. Mod Pathol. 1994 Aug;7(6):665-8.
- Koegelenberg CF, Irusen EM, von Groote-Bidlingmaier F, Bruwer JW, Batubara EM, Diacon AH. The utility of ultrasound-guided thoracentesis and pleural biopsy in undiagnosed pleural exudates. Thorax. 2015 Oct;70(10):995-7. doi: 10.1136/thoraxjnl-2014-206567. Epub 2015 May 21.
- Amiri Z, Momtahan M, Mokhtari M. Comparison of Conventional Cytology, Liquid-Based Cytology, and Cell Block in the Evaluation of Peritoneal Fluid in Gynecology Malignancies. Acta Cytol. 2019;63(1):63-72. doi: 10.1159/000495571. Epub 2019 Jan 9.
- Pak MG, Roh MS. Cell-blocks are suitable material for programmed cell death ligand-1 immunohistochemistry: Comparison of cell-blocks and matched surgical resection specimens in lung cancer. Cytopathology. 2019 Nov;30(6):578-585. doi: 10.1111/cyt.12743. Epub 2019 Jul 19.
- Metintas M, Yildirim H, Kaya T, Ak G, Dundar E, Ozkan R, Metintas S. CT Scan-Guided Abrams' Needle Pleural Biopsy versus Ultrasound-Assisted Cutting Needle Pleural Biopsy for Diagnosis in Patients with Pleural Effusion: A Randomized, Controlled Trial. Respiration. 2016;91(2):156-63. doi: 10.1159/000443483. Epub 2016 Jan 19.
- Hallifax RJ, Corcoran JP, Ahmed A, Nagendran M, Rostom H, Hassan N, Maruthappu M, Psallidas I, Manuel A, Gleeson FV, Rahman NM. Physician-based ultrasound-guided biopsy for diagnosing pleural disease. Chest. 2014 Oct;146(4):1001-1006. doi: 10.1378/chest.14-0299.
- Laursen CB, Naur TM, Bodtger U, Colella S, Naqibullah M, Minddal V, Konge L, Davidsen JR, Hansen NC, Graumann O, Clementsen PF. Ultrasound-guided Lung Biopsy in the Hands of Respiratory Physicians: Diagnostic Yield and Complications in 215 Consecutive Patients in 3 Centers. J Bronchology Interv Pulmonol. 2016 Jul;23(3):220-8. doi: 10.1097/LBR.0000000000000297.
- Bibby AC, Dorn P, Psallidas I, Porcel JM, Janssen J, Froudarakis M, Subotic D, Astoul P, Licht P, Schmid R, Scherpereel A, Rahman NM, Maskell NA, Cardillo G. ERS/EACTS statement on the management of malignant pleural effusions. Eur J Cardiothorac Surg. 2019 Jan 1;55(1):116-132. doi: 10.1093/ejcts/ezy258.
- Feller-Kopman DJ, Reddy CB, DeCamp MM, Diekemper RL, Gould MK, Henry T, Iyer NP, Lee YCG, Lewis SZ, Maskell NA, Rahman NM, Sterman DH, Wahidi MM, Balekian AA. Management of Malignant Pleural Effusions. An Official ATS/STS/STR Clinical Practice Guideline. Am J Respir Crit Care Med. 2018 Oct 1;198(7):839-849. doi: 10.1164/rccm.201807-1415ST.
- Willendrup F, Bodtger U, Colella S, Rasmussen D, Clementsen PF. Diagnostic accuracy and safety of semirigid thoracoscopy in exudative pleural effusions in Denmark. J Bronchology Interv Pulmonol. 2014 Jul;21(3):215-9. doi: 10.1097/LBR.0000000000000088.
- Rozman A, Camlek L, Marc-Malovrh M, Triller N, Kern I. Rigid versus semi-rigid thoracoscopy for the diagnosis of pleural disease: a randomized pilot study. Respirology. 2013 May;18(4):704-10. doi: 10.1111/resp.12066.
- Dhooria S, Singh N, Aggarwal AN, Gupta D, Agarwal R. A randomized trial comparing the diagnostic yield of rigid and semirigid thoracoscopy in undiagnosed pleural effusions. Respir Care. 2014 May;59(5):756-64. doi: 10.4187/respcare.02738. Epub 2013 Oct 8.
- Rahman NM, Ali NJ, Brown G, Chapman SJ, Davies RJ, Downer NJ, Gleeson FV, Howes TQ, Treasure T, Singh S, Phillips GD; British Thoracic Society Pleural Disease Guideline Group. Local anaesthetic thoracoscopy: British Thoracic Society Pleural Disease Guideline 2010. Thorax. 2010 Aug;65 Suppl 2:ii54-60. doi: 10.1136/thx.2010.137018. No abstract available.
- Light RW. Diagnostic principles in pleural disease. Eur Respir J. 1997 Feb;10(2):476-81. doi: 10.1183/09031936.97.10020476.
- Metintas M, Ak G, Dundar E, Yildirim H, Ozkan R, Kurt E, Erginel S, Alatas F, Metintas S. Medical thoracoscopy vs CT scan-guided Abrams pleural needle biopsy for diagnosis of patients with pleural effusions: a randomized, controlled trial. Chest. 2010 Jun;137(6):1362-8. doi: 10.1378/chest.09-0884. Epub 2010 Feb 12.
- Swiderek J, Morcos S, Donthireddy V, Surapaneni R, Jackson-Thompson V, Schultz L, Kini S, Kvale P. Prospective study to determine the volume of pleural fluid required to diagnose malignancy. Chest. 2010 Jan;137(1):68-73. doi: 10.1378/chest.09-0641. Epub 2009 Sep 9.
- Abouzgheib W, Bartter T, Dagher H, Pratter M, Klump W. A prospective study of the volume of pleural fluid required for accurate diagnosis of malignant pleural effusion. Chest. 2009 Apr;135(4):999-1001. doi: 10.1378/chest.08-2002. Epub 2008 Nov 18.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Neoplasms by Site
- Pleural Diseases
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Pleural Neoplasms
- Pleural Effusion, Malignant
- Pleural Effusion
- Physiological Effects of Drugs
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Sensory System Agents
- Anesthetics
- Anesthetics, Local
Other Study ID Numbers
- SJ-790
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pleural Effusion, Malignant
-
Sheng HuWuhan Binhui Biotechnology Co., Ltd.RecruitingMalignant Pleural Effusion | Malignant Peritoneal EffusionChina
-
Huazhong University of Science and TechnologyUnknownMalignant Ascites | Malignant Pleural Effusion,China
-
Clover Biopharmaceuticals AUS Pty LtdCompletedMalignant Pleural EffusionsAustralia
-
Singapore General HospitalCompletedMalignant Pleural EffusionsSingapore
-
Naestved HospitalTerminatedMalignant Pleural Effusion | Exudative Pleural EffusionDenmark
-
Johns Hopkins UniversityEnrolling by invitationMalignant Pleural EffusionsUnited States
-
Wuhan YZY Biopharma Co., Ltd.Not yet recruitingA Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLCNSCLC Stage IV | Malignant Pleural EffusionsChina
-
M.D. Anderson Cancer CenterTerminatedAdvanced Cancers | Malignant Pleural EffusionsUnited States
-
Eastern Regional Medical CenterRecruitingLoculated or Non-draining Malignant Pleural EffusionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingPleural NeoplasmUnited States
Clinical Trials on US-guided pleural biopsy
-
China-Japan Friendship HospitalRecruiting
-
Eskisehir Osmangazi UniversityCompletedPleural DiseasesTurkey
-
Nantes University HospitalCompleted
-
Eskisehir Osmangazi UniversityCompletedPleural Diseases | Pleural EffusionTurkey
-
Iuliu Hatieganu University of Medicine and PharmacyInstitutul Regional de Gastroenterologie & Hepatologie Prof. dr. Octavian...CompletedRetroperitoneal NeoplasmsRomania
-
Memorial Sloan Kettering Cancer CenterObafemi Awolowo University Teaching HospitalRecruiting
-
Heinrich-Heine University, DuesseldorfCompletedProstate CancerGermany
-
Peking University Cancer Hospital & InstituteUnknown
-
Icahn School of Medicine at Mount SinaiPhilips HealthcareUnknownProstate Disease | Elevated Prostate Specific Antigen | Family History of Prostate Cancer | Positive Digital Rectal ExamUnited States
-
Eskisehir Osmangazi UniversityCompletedDiagnosis of Pleural Diseases | Medical ThoracoscopyTurkey